| In vivo: |
| Clin Psychopharmacol Neurosci. 2015 Apr 30;13(1):109-12. | | Effect of Scopolamine Butylbromide on Clozapine-induced Hypersalivation in Schizophrenic Patients: A Case Series.[Pubmed: 25912544] | This study investigated the efficacy of the anticholinergic agent Scopolamine butylbromide against clozapine-induced hypersalivation.
METHODS AND RESULTS:
Five schizophrenia patients were coadministered Scopolamine butylbromide (30-60 mg/ day) for 4 weeks. At the baseline and after 4 weeks' treatment, we subjectively evaluated hypersalivation using a visual analog scale and objectively assessed it using the Drooling Severity Scale and Drooling Frequency Scale. As a result, improvements in the patients' Drooling Severity Scale and Drooling Frequency Scale scores, but no improvements in their visual analog scale scores, were observed after Scopolamine butylbromide treatment. These results indicate that at least some schizophrenic patients with clozapine-induced hypersalivation would benefit from Scopolamine butylbromide treatment.
CONCLUSIONS:
We conclude that clozapine-induced hypersalivation is one factor of stress to patients. Subjective hypersalivation was not improved, but objective hypersalivation was, by Scopolamine butylbromide treatment. However, Scopolamine butylbromide and clozapine possess anticholinergic effects so clinicians should closely monitor patients who take Scopolamine butylbromide. | | World J Surg Oncol. 2015 Feb 15;13:50. | | Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer.[Pubmed: 25889313] | The aim of this randomized controlled study was to determine whether octreotide (OCT) or Scopolamine butylbromide (SB) was the more effective antisecretive drug controlling gastrointestinal (GI) symptoms due to malignant bowel obstruction (MBO) caused by advanced ovarian cancer.
METHODS AND RESULTS:
Ninety-seven advanced ovarian cancer patients with inoperable MBO were randomized to OCT 0.3 mg/day (OCT group, n = 48) or Scopolamine butylbromide 60 mg/day (Scopolamine butylbromide group, n = 49) for 3 days through a continuous subcutaneous infusion. One patient in the Scopolamine butylbromide group is not included in any assessments since she withdrew consent prior to receiving any treatment because of rapidly progressing cancer. OCT significantly reduced the amount of GI secretions at T1, T2, and T3 (P < 0.05) compared with Scopolamine butylbromide. NGT secretions significantly reduced at T1, T2, and T3 compared with T0 (P < 0.05) in the OCT group, while in the Scopolamine butylbromide group, only at T3, NGT secretions significantly reduced compared with T0. OCT treatment induced a significantly rapid reduction in the number of daily episodes of vomiting and intensity of nausea compared with Scopolamine butylbromide treatment. No significant changes were observed in dry mouth, drowsiness, and colicky pain after either drug. Continuous pain values were significantly lower in the OCT group than in the Scopolamine butylbromide group at T2 and T3 (P < 0.05).
CONCLUSIONS:
At the doses used in this study, OCT was more effective than Scopolamine butylbromide in controlling gastrointestinal symptoms of bowel obstruction. Further studies are necessary to understand the role of hydration more clearly in such a clinical situation. | | Masui. 1992 Apr;41(4):670-2. | | Scopolamine butylbromide (0.2 mg.kg-1) prevents succinylcholine-induced bradycardia in infants and children.[Pubmed: 1578626] |
METHODS AND RESULTS:
We evaluated the effectiveness of scopolamine butylbromide in preventing succinylcholine-induced bradycardia in infants and children. Forty-two infants and children were randomly assigned into two groups. In group I, 0.2 mg.kg-1 and in group II, 0.4 mg.kg-1 of scopolamine butylbromide in mixture with succinylcholine (2 mg.kg-1) was administered after halothane induction. HR decreased significantly after halothane induction. Following the injection of the mixture, HR increased above the preinduction value within 20 seconds without any decrease in HR. HR changes were identical in the two groups.
CONCLUSIONS:
In conclusion, scopolamine butylbromide (0.2 mg.kg-1) was effective in preventing succinylcholine-induced bradycardia in infants and children. |
|
Cell. 2018 Jan 11;172(1-2):249-261.e12. doi: 10.1016/j.cell.2017.12.019.IF=36.216(2019)
Cell Metab. 2020 Mar 3;31(3):534-548.e5. doi: 10.1016/j.cmet.2020.01.002.IF=22.415(2019)
Mol Cell. 2017 Nov 16;68(4):673-685.e6. doi: 10.1016/j.molcel.2017.10.022.IF=14.548(2019)
ACS Nano. 2018 Apr 24;12(4): 3385-3396. doi: 10.1021/acsnano.7b08969.IF=13.903(2019)
Nature Plants. 2016 Dec 22;3: 16206. doi: 10.1038/nplants.2016.205.IF=13.297(2019)
Sci Adv. 2018 Oct 24;4(10): eaat6994. doi: 10.1126/sciadv.aat6994.IF=12.804(2019)
